{"id":"W3039517308","doi":"10.1016/j.clml.2020.07.001","title":"Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Janssen Biotech; Sanofi Pasteur; Celgene; Sanofi; Takeda Canada; MaaT Pharma; Therakos; Novartis; British Microcirculation Society; Amgen; Pfizer; Astellas Pharma; Roche","keywords":"Gemtuzumab ozogamicin; Medicine; Calicheamicin; Hepatic veno-occlusive disease; Myeloid leukemia; Internal medicine; Salvage therapy; Hematopoietic stem cell transplantation; CD33; Toxicity; Chemotherapy; Cytarabine; Gastroenterology; Transplantation; Oncology; Surgery; Stem cell; CD34","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003108774,0.0003549486,0.0009246076,0.0002580418,0.000299278,0.000350185,0.0002287938,0.0002664972,0.0006149492],"category_scores_gemma":[0.0005792613,0.0001123158,0.0004855197,0.0003813597,0.0002168019,0.0002634572,0.0002403198,0.0006336932,0.00008824846],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000434788,"about_ca_system_score_gemma":0.0005442851,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007037732,"about_ca_topic_score_gemma":0.002218345,"domain_scores_codex":[0.9998543,0.0000478869,0.00001528502,0.00002120343,0.00001758208,0.00004362877],"domain_scores_gemma":[0.9998048,0.00004506296,0.00004756811,0.000009890799,0.000007911516,0.0000848765],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1273664,0.003423224,0.4717266,0.0009067641,0.002103825,0.009168464,0.0004279249,0.002770414,0.02624412,0.0006949471,0.005607369,0.3495599],"study_design_scores_gemma":[0.0112522,0.03354781,0.9254537,0.0002296723,0.002314434,0.01028952,0.0003237292,0.002672466,0.003442815,0.0008307385,0.009586984,0.00005610296],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920739,0.006089789,0.0001646185,0.0002825551,0.00007527402,0.00004556105,0.00008106867,0.00001549659,0.001171892],"genre_scores_gemma":[0.9980785,0.001138002,0.0001323399,0.0002034928,0.00008899844,0.00002711086,0.0001819765,0.000002395601,0.0001471992],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009246076,"threshold_uncertainty_score":0.003154635,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01630102654172014,"score_gpt":0.2704746716757513,"score_spread":0.2541736451340311,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}